This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down about 75% from a high-water mark they set last December. Up and down Wall Street, investment bank analysts tasked with following the commercial-stage cancer drug developer are arguing about whether it's fallen too far or not far enough.Over at Chardan Capital, Geulah Livshits reiterated a buy rating and a $25 price target on July 23. From the stock's price of $3.05 on the morning of July 28, Livshits' estimate implies a gain of about 720% in about a year.Not every investment bank is as enthusiastic about Iovance as Chardan Capital, but expectations are still extremely high. When the market opened on July 28, the consensus price target on the stock was $10 per share.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool